Edinburgh Biosciences, the developer of a non-surgical cataract treatment, has secured a £2.3m loan investment from Contamac, with whom it shared a major mutual shareholder.
The funding will support the commercial launch of Revisyon, the company’s new technology, which was entering its final phase before market introduction, following the completion of clinical trials.
With a UKCA mark anticipated by the end of the year, Revisyon could shift cataract treatment away from the operating theatre and onto the high street, shortening the care pathway for millions awaiting surgery.
Commenting on the investment, CEO Graham Bell said: ‘We have backers who support our vision and are equally excited about the global possibilities presented by Revisyon.’
